# Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL)

> **NCT06843122** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Medical University of Warsaw** · enrollment: 105 (estimated)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **BIOLOGICAL:** A - Allogenic ADSC cells in fibrin solution - two times administration ADSC/ASC
- **BIOLOGICAL:** B - Allogenic ADSC cells in fibrin solution - one time administration of ADSC/ASC, one time of placebo
- **OTHER:** C - Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.

## Key facts

- **NCT ID:** NCT06843122
- **Lead sponsor:** Medical University of Warsaw
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-08
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-08-01
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06843122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06843122, "Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06843122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*